INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 30 September 2017
Net Assets |
£241m |
Net Assets per share |
642p |
Share price |
605p |
Total value of unquoted investments |
£17m |
Total number of portfolio companies |
93 |
Dividend |
4% of NAV per annum |
Top Ten Quoted Investments
Company Name |
% NAV |
Celgene |
8.1 |
Biogen |
6.9 |
Regeneron |
5.7 |
Vertex |
4.2 |
Alexion |
4.0 |
Shire |
3.6 |
Incyte |
3.2 |
Gilead |
3.1 |
Acadia |
2.8 |
Adamas |
2.6 |
|
----------- |
Total |
44.2 |
Geographical Allocation |
% NAV |
US & Canada |
86 |
Europe & UK |
14 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
91 |
Unquoted |
9 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
45 |
Mid Cap =USD1-10BN |
31 |
Small Cap <USD1BN |
24 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
35 |
Rare diseases |
15 |
CNS |
13 |
Ophthalmology |
8 |
Inflammation |
8 |
Infectious Diseases |
5 |
Metabolic |
5 |
Medtech |
2 |
Other |
9 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
20 OCTOBER 2017